Lisa Bregoli

Lisa Bregoli

Auto-generated profile, based on publicly available information

Lisa Bregoli

Department of Clinical Medicine, Institute of Molecular Medicine (IMM), School of Medicine, Trinity College Dublin, Dublin 8, Ireland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2007 in Science
Verified
Journal Article
Closed access
PDF file
AAAna C. Anderson
Ana C. Anderson
DADavid E. Anderson
David E. Anderson
LBLisa Bregoli
Lisa Bregoli
WHWilliam D. Hastings
William D. Hastings
NKNasim Kassam
Nasim Kassam
DHDavid A. Hafler
David A. Hafler
CD4 + T helper 1 (T H 1) cells are important mediators of inflammation and are regulated by numerous pathways, including the negative immune receptor Tim-3. We found that Tim-3 is constitutively expressed on cells of the innate immune system in both mice and humans, and that it can synergize with Toll-like receptors. Moreover, an antibody agonist of Tim-3 acted as an adjuvant during induced immune responses, and Tim-3 ligation induced distinct signaling events in T cells and dendritic cells; the latter finding could explain the apparent divergent functions of Tim-3 in these cell types. Thus, by virtue of differential expression on innate versus adaptive immune cells, Tim-3 can either promote or terminate T H 1 immunity and may be able to influence a range of inflammatory conditions.

1 May 2005 in Nature
Verified
Journal Article
Closed access
PDF file
SKSally C. Kent
Sally C. Kent
YCYahua Chen
Yahua Chen
LBLisa Bregoli
Lisa Bregoli
SCSue M. Clemmings
Sue M. Clemmings
NKNorma Sue Kenyon
Norma Sue Kenyon
DHDavid A. Hafler
David A. Hafler

1 January 2016 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Open access
LBLisa Bregoli
Lisa Bregoli
DMDania Movia
Dania Movia
JGJames D. Gavigan-Imedio
James D. Gavigan-Imedio
JLJoanne Lysaght
Joanne Lysaght
JRJohn Reynolds
John Reynolds
APAdriele Prina-Mello
Adriele Prina-Mello
The high global incidence of cancer is associated with high rates of mortality and morbidity worldwide. By taking advantage of the properties of matter at the nanoscale, nanomedicine promises to develop innovative drugs with greater efficacy and less side effects than standard therapies. Here, we discuss both clinically available anti-cancer nanomedicines and those en route to future clinical application. The properties, therapeutic value, advantages and limitations of these nanomedicine products are highlighted, with a focus on their increased performance versus conventional molecular anticancer therapies. The main regulatory challenges toward the translation of innovative, clinically effective nanotherapeutics are discussed, with a view to improving current approaches to the clinical management of cancer. Ultimately, it becomes clear that the critical steps for clinical translation of nanotherapeutics require further interdisciplinary and international effort, where the whole stakeholder community is involved from bench to bedside. From the Clinical Editor: Cancer is a leading cause of mortality worldwide and finding a cure remains the holy-grail for many researchers and clinicians. The advance in nanotechnology has enabled novel strategies to develop in terms of cancer diagnosis and therapy. In this concise review article, the authors described current capabilities in this field and outlined comparisons with existing drugs. The difficulties in bringing new drugs to the clinics were also discussed.

13 December 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
SGS A Greenberg
S A Greenberg
EBE M Bradshaw
E M Bradshaw
JPJ L Pinkus
J L Pinkus
GPG S Pinkus
G S Pinkus
TBT Burleson
T Burleson
AAA A Amato
A A Amato
Background: Previous immunohistochemical studies of muscle from patients with inclusion body myositis and polymyositis found many more T cells than B cells, suggesting a role for intramuscular cell-mediated immune mechanisms rather than humoral mechanisms. Methods: Microarray studies were performed on muscle biopsy specimens from 40 patients with inclusion body myositis (IBM; n = 23), polymyositis (PM; n = 6), and without neuromuscular disease (n = 11). Reverse transcription PCR of selected immunoglobulin gene transcripts was performed on two patient samples. Qualitative immunohistochemical studies for B-cell lineage cell surface markers were performed on 28 muscle specimens and quantitative studies performed on a subset of 19 untreated patients with IBM or PM. CD138+ cells were isolated from muscle using laser capture microdissection, and immunoglobulin transcripts were PCR amplified to determine the presence or absence of immunoglobulin gene rearrangements unique to the B-cell lineage. Results: Immunoglobulin gene transcripts accounted for 59% in IBM and 33% in PM of the most stringently defined highest differentially expressed muscle transcripts compared with normal. Plasma cells, terminally differentiated B cells expressing CD138 but not CD19 or CD20, are present in IBM and PM muscle in numbers several times higher than B cells. Conclusions: There are differentiated B cells in the form of CD138+ plasma cells within the muscle of patients with inclusion body myositis and polymyositis. The principle of linked recognition of B-cell activation predicts several strategies for autoantigen discovery that could not otherwise be pursued through the study of the infiltrating T-cell population alone.

1 August 2005 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
KOKevin C. O’connor
Kevin C. O’connor
HAHeiner Appel
Heiner Appel
LBLisa Bregoli
Lisa Bregoli
MCMatthew E. Call
Matthew E. Call
ICIngrid Catz
Ingrid Catz
KWKai W. Wucherpfennig
Kai W. Wucherpfennig
Autoantibodies to myelin oligodendrocyte glycoprotein (MOG) can induce demyelination and oligodendrocyte loss in models of multiple sclerosis (MS). Whether anti-MOG Abs play a similar role in patients with MS or inflammatory CNS diseases by epitope spreading is unclear. We have therefore examined whether autoantibodies that bind properly folded MOG protein are present in the CNS parenchyma of MS patients. IgG was purified from CNS tissue of 14 postmortem cases of MS and 8 control cases, including cases of encephalitis. Binding was assessed using two independent assays, a fluorescence-based solid-phase assay and a solution-phase RIA. MOG autoantibodies were identified in IgG purified from CNS tissue by solid-phase immunoassay in 7 of 14 cases with MS and 1 case of subacute sclerosing panencephalitis, but not in IgG from noninflamed control tissue. This finding was confirmed with a solution-phase RIA, which measures higher affinity autoantibodies. These data demonstrate that autoantibodies recognizing MOG are present in substantially higher concentrations in the CNS parenchyma compared with cerebrospinal fluid and serum in subjects with MS, indicating that local production/accumulation is an important aspect of autoantibody-mediated pathology in demyelinating CNS diseases. Moreover, chronic inflammatory CNS disease may induce autoantibodies by virtue of epitope spreading.

26 May 2014 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
CLCarmen Losasso
Carmen Losasso
SBSimone Belluco
Simone Belluco
VCVeronica Cibin
Veronica Cibin
PZPaola Zavagnin
Paola Zavagnin
IMIvan Miäetiä
Ivan Miäetiä
ARAntonia Ricci
Antonia Ricci
Salmonella spp. is one of the main causes of foodborne illnesses in humans worldwide. Consequently, great interest exists in reducing its impact on human health by lowering its prevalence in the food chain. Antimicrobial formulations in the form of nanoparticles exert bactericidal action due to their enhanced reactivity resultant from their high surface/volume ratio. Silver nanoparticles (AgNPs) are known to be highly toxic to Gram-negative and Gram-positive microorganisms, including multidrug resistant bacteria. However, few data concerning their success against different Salmonella serovars are available. Aims of the present study were to test the antimicrobial effectiveness of AgNPs, against Salmonella Enteritidis, Hadar and Senftenberg, and to investigate the causes of their different survival abilities from a molecular point of view.Results showed an immediate, time-limited and serovar-dependent reduction of bacterial viability. In the case of S. Senftenberg, the reduction in numbers was observed for up to 4 h of incubation in the presence of 200 mg/L of AgNPs; on the contrary, S. Enteritidis and S. Hadar resulted to be inhibited for up to 48 h. RT-PCR experiments demonstrated the constitutive expression of the plasmidic silver resistance determinant (SilB) by S. Senftenberg, thus suggesting the importance of a cautious use of AgNPs.